Julia Wolfe
Memorial Sloan Kettering Cancer Center
12 Papers
54 Citations
Julia Wolfe is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Ibrutinib & Progression-free survival. The author has an hindex of 7, co-authored 12 publications.
Chat about Author
Papers
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Christian Grommes,Christian Grommes,Alessandro Pastore,Nicolaos Palaskas,Sarah S. Tang,Carl Campos,Derrek Schartz,Paolo Codega,Donna Nichol,Owen Clark,Wan-Ying Hsieh,Daniel Rohle,Marc K. Rosenblum,Agnes Viale,Viviane Tabar,Cameron Brennan,I. T. Gavrilovic,I. T. Gavrilovic,Thomas Kaley,Thomas Kaley,Craig Nolan,Craig Nolan,Antonio M. P. Omuro,Antonio M. P. Omuro,Elena Pentsova,Elena Pentsova,Alissa A. Thomas,Elina Tsyvkin,Elina Tsyvkin,Ariela Noy,Ariela Noy,M. Lia Palomba,M. Lia Palomba,Paul A. Hamlin,Paul A. Hamlin,Craig S. Sauter,Craig S. Sauter,Craig H. Moskowitz,Craig H. Moskowitz,Julia Wolfe,Ahmet Dogan,Minhee Won,Jon Glass,Scott Peak,Enrico C. Lallana,Vaios Hatzoglou,Anne S. Reiner,Philip H. Gutin,Jason T. Huse,Katherine S. Panageas,Thomas G. Graeber,Nikolaus Schultz,Lisa M. DeAngelis,Lisa M. DeAngelis,Ingo K. Mellinghoff,Ingo K. Mellinghoff +55 more
TL;DR: Ibrutinib has substantial activity in patients with relapsed or refractory B-cell lymphoma of the CNS, and combined inhibition of BTK and PI3K/mTOR may augment the ibrut inib response in CD79B-mutant human PCNSLs.
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
Christian Grommes,Christian Grommes,Sarah S. Tang,Julia Wolfe,Thomas Kaley,Mariza Daras,Elena Pentsova,Anna F. Piotrowski,Jacqueline B. Stone,Andrew L. Lin,Craig Nolan,Malbora Manne,Paolo Codega,Carl Campos,Agnes Viale,Alissa A. Thomas,Michael F. Berger,Michael F. Berger,Vaios Hatzoglou,Anne S. Reiner,Katherine S. Panageas,Lisa M. DeAngelis,Ingo K. Mellinghoff +22 more
TL;DR: The combination of ibrutinib, HD-MTX, and rituximab was tolerated with an acceptable safety profile and sustained tumor responses were associated with clearance of ctDNA from the CSF.
212
Mechanisms of Ischemic Stroke in Patients with Cancer: A Prospective Study
Babak B. Navi,Babak B. Navi,Carla P Sherman,Richard Genova,Ryna Mathias,Kelsey N Lansdale,Natalie M LeMoss,Julia Wolfe,Anna Skakodub,Hooman Kamel,Scott T. Tagawa,Ashish Saxena,Allyson J. Ocean,Gerald A. Soff,Maria T. DeSancho,Costantino Iadecola,Mitchell S.V. Elkind,Ellinor I.B. Peerschke,Cenai Zhang,Lisa M. DeAngelis +19 more
TL;DR: In this article, the authors examined the pathophysiology of ischemic stroke with cancer and found that patients with cancer-related stroke have higher markers of coagulation, platelet, and endothelial dysfunction than matched controls.
48
Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma
Christian Grommes,Alessandro Pastore,Igor T. Gavrilovic,Thomas Kaley,Craig Nolan,Antonio Omuro,Julia Wolfe,Elena Pentsova,Vaois Hatzoglou,Ingo K. Mellinghoff,Lisa M. DeAngelis +10 more
TL;DR: Patients with CNS lymphoma tolerate Ibrutinib with manageable adverse events and drug concentrations in CSF are higher at steady state (day 29) and meaningful CSF concentrations are reached, as well as in vitro to reduce growth of lymphoma cells.
27
Cancer-Related Ischemic Stroke Has a Distinct Blood mRNA Expression Profile
Babak B. Navi,Babak B. Navi,Ryna Mathias,Carla P Sherman,Julia Wolfe,Hooman Kamel,Scott T. Tagawa,Ashish Saxena,Allyson J. Ocean,Costantino Iadecola,Lisa M. DeAngelis,Lisa M. DeAngelis,Mitchell S.V. Elkind,Heather Hull,Glen C. Jickling,Frank R. Sharp,Bradley P. Ander,Boryana Stamova +17 more
TL;DR: Evidence for a distinctive molecular signature in blood mRNA expression profiles of patients with cancer-related AIS is provided, and future studies should evaluate whether blood mRNA can predict detection of occult cancer in patients with AIS.
19